Patrizia Cavazzoni
{{Short description|American physician}}
{{Infobox officeholder
| name = Patrizia Cavazzoni
| image = Patrizia Cavazzoni.png
| caption = Official FDA Portrait
| office = Director of the Center for Drug Evaluation and Research{{cite web|url=https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-leadership-bios|archive-url=https://web.archive.org/web/20190911093756/https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-leadership-bios|url-status=dead|archive-date=September 11, 2019|title=CDER Leadership Bios|date=April 12, 2021|publisher=U.S. Food and Drug Administration}}
| term_start = April 12, 2021
Acting: May 2020 – April 2021
| term_end =
| predecessor = Janet Woodcock
| successor = Jacqueline Corrigan-Curay (acting)
| office1 = Acting Principal Deputy Commissioner of Food and Drugs{{cite web|url=https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/patrizia-cavazzoni|title=Patrizia Cavazzoni M.D.|date=April 12, 2021|publisher=U.S. Food and Drug Administration}}
| term_start1 = January 2019
| term_end1 = February 2019
| successor1 = Amy Abernethy
| office2 = Deputy Center Director for Operations of the FDA Center for Drug Evaluation and Research
| term_start2 = January 2018
| term_end2 = May 2020
| education = McGill University (MD){{cite web|url=https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/patrizia-cavazzoni|title=Patrizia Cavazzoni M.D.|date=April 12, 2021|publisher=U.S. Food and Drug Administration}}
}}
Patrizia Cavazzoni was the director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). Prior to this position she worked at Pfizer and had been a psychiatrist. She resigned from FDA on January 10, 2025, ten days before Donald Trump took office.{{Cite web |last=Feuerstein |first=Lizzy Lawrence, Adam |date=2025-01-10 |title=Patrizia Cavazzoni, head of FDA's drug center, to leave the agency |url=https://www.statnews.com/2025/01/10/fda-patrizia-cavazzoni-drug-center-head-leaving/ |access-date=2025-01-10 |website=STAT |language=en-US}}
Education
Cavazzoni earned her medical degree from McGill University and subsequently was a fellow at the University of Ottawa.{{cite web|url=https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/patrizia-cavazzoni|title=Patrizia Cavazzoni M.D.|date=April 12, 2021|publisher=U.S. Food and Drug Administration}} She then joined the University of Ottawa as an assistant professor before moving to the pharmaceutical industry,{{Cite web |date=2019-09-22 |title=Patricia Cavazzoni |url=https://heal.nih.gov/about/patrizia-cavazzoni |access-date=2022-03-30 |website=NIH HEAL Initiative |language=en}} where she worked at Pfizer.
She moved to the U.S. Food and Drug Administration in 2018, and was named acting director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research in 2020{{Cite news |last=Florko |first=Nicholas |date=June 23, 2020 |title=The new Janet: The FDA turns to a quiet problem-solver who brings expertise – and a little controversy |work=STAT; Boston |id={{ProQuest| }}}}{{Cite news |last=Florko |first=Nicholas |date=May 22, 2020 |title=FDA shuffles longtime division head, Janet Woodcock, to focus exclusively on Covid-19 vaccine project |work=STAT; Boston |id={{ProQuest| }}}} and director in 2021.{{Cite web |last=Oakes |first=Kari |date=April 21, 2021 |title=Cavazzoni named to permanent CDER director role |url=https://www.raps.org/news-and-articles/news-articles/2021/4/cavazzoni-named-to-permanent-cder-director-role |access-date=2022-03-30 |website=www.raps.org}} During the COVID-19 pandemic, Cavazzoni has spoken publicly about the need for science to guide policies{{Cite web |last=Zeller |first=Patrizia Cavazzoni, Peter Marks, Susan Mayne, Judy McMeekin, Jeff Shuren, Steven Solomon, Janet Woodcock and Mitch |date=10 September 2020 |title=Senior FDA career executives: We're following the science to protect public health in pandemic |url=https://www.usatoday.com/story/opinion/2020/09/10/sound-science-to-meet-covid-challenges-fda-career-officials-column/5756948002/ |access-date=2022-03-30 |website=USA TODAY |language=en-US}} and about the future of the Center for Drug Evaluation and Research after the COVID-19 pandemic.{{Cite web |last=Oakes |first=Kari |date=21 May 2021 |title=Cavazzoni paints CDER's post-pandemic future |url=https://www.raps.org/news-and-articles/news-articles/2021/5/cavazzoni-paints-cders-post-pandemic-future |access-date=2022-03-30 |website=www.raps.org}} She also noted that she would hand Donald Trump a blank sheet of paper if asked to submit a list of workers who should not receive due process protections.{{Cite news |last=Hohmann |first=James |date=November 3, 2020 |title=Analysis {{!}} The Daily 202: Election pits Trump vs. the experts |language=en-US |newspaper=Washington Post |url=https://www.washingtonpost.com/politics/2020/11/03/daily-202-election-pits-trump-vs-experts/ |access-date=2022-03-30 |issn=0190-8286}}
Research
While she worked at the Royal Ottawa Hospital, Cavazzoni examined the link between genetics and personality, and the chemicals implicated in brain chemistry.{{Cite news |last=Sibbald |first=Barbara |date=30 May 1999 |title=Busting the happiness barrier: Scientists are searching for common ground to make us happier |pages=C3 |work=The Ottawa Citizen |id={{ProQuest| }}]}} She further examined the connections between diabetes and patients receiving antipsychotic medications.{{Cite journal |last1=Cavazzoni |first1=Patrizia |last2=Mukhopadhyay |first2=Nitai |last3=Carlson |first3=Christopher |last4=Breier |first4=Alan |last5=Buse |first5=John |date=2004 |title=Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications |journal=British Journal of Psychiatry |language=en |volume=184 |issue=S47 |pages=s94–s101 |doi=10.1192/bjp.184.47.s94 |pmid=15056601 |s2cid=15936219 |issn=0007-1250|doi-access=free }}
Selected publications
- {{Cite journal |last1=Buse |first1=John B. |last2=Cavazzoni |first2=Patrizia |last3=Hornbuckle |first3=Kenneth |last4=Hutchins |first4=David |last5=Breier |first5=Alan |last6=Jovanovic |first6=Lois |date=2003-02-01 |title=A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States |url=https://www.jclinepi.com/article/S0895-4356(02)00588-7/abstract |journal=Journal of Clinical Epidemiology |language=English |volume=56 |issue=2 |pages=164–170 |doi=10.1016/S0895-4356(02)00588-7 |issn=0895-4356 |pmid=12654411|url-access=subscription }}
- {{Cite journal |last1=Breier |first1=Alan |last2=Berg |first2=Paul H. |last3=Thakore |first3=Jogin H. |last4=Naber |first4=Dieter |last5=Gattaz |first5=Wagner F. |last6=Cavazzoni |first6=Patrizia |last7=Walker |first7=Daniel J. |last8=Roychowdhury |first8=Suraja M. |last9=Kane |first9=John M. |date=2005-10-01 |title=Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia |url=https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.162.10.1879 |journal=American Journal of Psychiatry |volume=162 |issue=10 |pages=1879–1887 |doi=10.1176/appi.ajp.162.10.1879 |pmid=16199834 |issn=0002-953X|url-access=subscription }}
- {{Cite journal |last=Cavazzoni |first=P |date=2003 |title=Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial |url=https://linkinghub.elsevier.com/retrieve/pii/S0924977X0200127X |journal=European Neuropsychopharmacology |language=en |volume=13 |issue=2 |pages=81–85 |doi=10.1016/S0924-977X(02)00127-X|pmid=12650950 |s2cid=43289579 |url-access=subscription }}
Honors and awards
Cavazzoni received the American College of Psychiatrists's Laughlin Fellowship.{{When|date=March 2022}}
References
{{reflist}}
{{Authority control}}
{{DEFAULTSORT:Cavazzoni, Patrizia}}
Category:McGill University alumni